Burns Clinical Trial - Optimal Heating Temperature in Major Burns Patients

Status Not yet recruiting

Clinical Trial Summary

pre and post intervention quasi-experimental epidemiological study without a control group will be carried out in large burned patients that will evaluate the influence on metabolic expenditure of the inclusion of active external rewarming in the control of body temperature.

Clinical Trial Description

the heavily burned patient requires specific care to prevent hypothermia and maintain body temperature. You are at high risk of developing hypothermia in the acute phase due to heat losses from convection, radiation, evaporation, and conduction. After the acute phase, the patient due to physiological mechanisms and the hypermetabolic response mainly demands a temperature close to 38.5ºC, ruling out the infectious focus. According to the authors, environmental temperatures between 28-33ºC are recommended for the care of these patients to decrease energy expenditure. The research carried out has studied the influence of passive external heating (environmental regulation), without including the influence of active external heating (heat blankets, heating plate ...) or the study of the thermal comfort of large burned patients and of professionals who provide them they attend.

A pre and post intervention quasi-experimental epidemiological study without a control group will be carried out in large burned patients that will evaluate the influence on metabolic expenditure of the inclusion of active external rewarming in the control of body temperature. Metabolic expenditure will be measured by indirect calorimetry in the usual treatment with passive external rewarming and post-intervention in the combination of passive and active external heating. The combination of passive and active external reheating will previously study the operating temperature in various cases for optimal application, as well as the definition of thermal comfort in the large burn unit. The specific training of the personnel involved in the care of these patients will be required for the application of the evidence-based recommendations and the evaluation of their implementation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04396951
Study type	Interventional
Source	University Rovira i Virgili
Contact	Juan Manuel Alonso Fernández, MSN
Phone	0034679660502
Email	jmalonsof@gmail.com
Status	Not yet recruiting
Phase	N/A
Start date	September 1, 2020
Completion date	October 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05023135` - DeepView SnapShot Portable (DV-SSP): Device Training Study
Completed	`NCT05276869` - Reliability and Feasibility of WeeFIM Instrument to Measure Functional Independence in Pediatric Burns
Completed	`NCT04548635` - VR for Burn Dressing Changes at Home	Phase 2/Phase 3
Not yet recruiting	`NCT06076031` - Effects of Applying Streaming Media on Reducing Pain in Patient With Second-degree Burn During Changing Dressing	N/A
Recruiting	`NCT05084248` - Vitamin D Deficiency in Adults Following a Major Burn Injury	Phase 4
Completed	`NCT03113253` - TRANexamic Acid to Reduce Bleeding in BURN Surgery	Phase 4
Recruiting	`NCT04090424` - Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns	N/A
Not yet recruiting	`NCT05649891` - Checklists Resuscitation Emergency Department	N/A
Withdrawn	`NCT03159182` - Study of Silicone Material Inserts To Treat Burn Scars	N/A
Recruiting	`NCT02904941` - Human Amniotic Versus Synthetic Membrane as a Transient Skin Cover for Pediatric Burns	N/A
Completed	`NCT02681757` - Comparison of Mepitel Ag vs Antibiotic Ointment Used With Soft Cast Technique for Treatment of Pediatric Burns	N/A
Recruiting	`NCT01812941` - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients	N/A
Completed	`NCT01437852` - StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns	Phase 1
Completed	`NCT01214811` - Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing	Phase 3
Completed	`NCT01061502` - Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds	Phase 1/Phase 2
Terminated	`NCT00822796` - Thermogard™ Efficacy Trial	N/A
Terminated	`NCT00824681` - Effect of Music Therapy on Families of Burn Patients	Phase 1
Terminated	`NCT00634166` - Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group	Phase 4
Terminated	`NCT00464386` - Continuous Glucose Monitoring (POC) in the ICU	N/A
Withdrawn	`NCT00216983` - Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.